AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06008899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US assisted caudal epidural pulsed radiofrequency
Description: patients will receive US assisted caudal epidural pulsed radiofrequency and followed up to 8 weeks
Study NCT06002984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Neuromonitoring to find EBSLN
Description: intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
Study NCT05135481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phrenectomy
Description: The qualification for phrenectomy in group 1 will be made based on the Amir scale, i.e. a score of 4 and fewer points for the language function (2).
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 10 mg Group
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10 mg Group
Description: 6 subjects will receive TPN171H 10 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 30 mg Group
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 30 mg Group
Description: 6 subjects will receive TPN171H 30 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 40 mg Group
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 40 mg Group
Description: 6 subjects will receive TPN171H 40 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPN171H 50 mg Group
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05750355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 50 mg Group
Description: 6 subjects will receive TPN171H 50 mg, orally; 2 subjects will receive placebo, orally.
Study NCT05158868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HiF-1 alpha measurement
Description: HIF1- α is a heterodimeric transcription factor that bind to hypoxia response elements, which participates through the regulation of the expression of several genes in numerous cellular events such as O2 sensing, glucose metabolism, lipid metabolism, angiogenesis and other aspects of endothelial biology
Study NCT05375695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.~Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care.
Study NCT05781295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaurolockTM
Description: The patient will be followed up to a maximum of 6 months after randomization after have a TaurolockTM injected each time catheter will be used.
Study NCT05781295 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: The patient will be followed up to a maximum of 6 months after randomization after have a Physiological serum injected each time catheter will be used.
Study NCT05237479 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprainguinal fascia ilica block
Description: Patients who have been randomized to Group B Intervention will receive a preoperative S-FICB using 35ml of 0.5% ropivacaine under ultrasound guidance by the regional anesthesia block team once patient has been marked by surgeon. Sensory \& motor distribution of the LFCN, FN, \& ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery. Patients who received a S-FICB in preop, approximately 15 minutes after the block, sensory \& motor distribution of LFCN, FN, \& ON will be assessed by the regional anesthesia block team prior to going to the operating room. All patients, regardless of group allocation, will be followed by the acute pain service team on postoperative day one to assess sensory \& motor distribution of LFCN, FN, \& ON \& adjustment of pain medication regimens. All patients will receive a call from a research assistant blinded to group allocation 24 hours post-discharge for a patient satisfaction survey.
Study NCT05237479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The sensory and motor distribution of the LFCN, FN, and ON will be assessed by the regional anesthesia team in the preop area for patients randomized to the control group prior to surgery.
Study NCT05466747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RYMPHYSIA
Description: RYMPHYSIA administered through an IV injection.
Study NCT05466747 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Another Available A1PI
Description: Another available A1PI administered through an IV injection.
Study NCT05778786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys 1 Day for Astigmatism
Description: CONTROL
Study NCT05778786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRA100/TRA200 series toric contact lens with HEVL-blocking chromophore
Description: TEST
Study NCT05384067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: Participants will complete one mindfulness education module every week for 4 weeks, and to practice a 15-minute formal guided mindfulness meditation at least five times per week across the 4 weeks. Participants will also be taught evidence-based sleep improvement techniques, will be provided education for when to use the techniques, and will be encouraged to implement the techniques to improve sleep.
Study NCT04854811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Roflumilast Oral Tablet
Description: Once daily for 12 weeks
Study NCT04854811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Oral Tablet
Description: Once daily for 12 weeks
Study NCT05135481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased lactation support
Description: Management in group 2 will include increased lactation care both during hospital stay and post discharge.
Study NCT06279793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids
Description: Omegaven® is a 10% fish oil emulsion supplement with a high percentage of long-chain n-3 fatty acids - mainly eicosapentaenoic acid and docosahexaenoic acid. It is a lipid emulsion supplement that optimises the fatty acid pattern in parenteral nutrition and is a source of polyunsaturated n-3 fatty acids as cell membrane components and precursors for eicosanoids.~Omegaven® is manufactured by Fresenius-Kabi, Germany and is available in 100 mL bottles for study purpose.~Each 100 mL of Omegaven® contains 10 g of fish oil (0.1 g/mL).~Timeframe:~Day -1: 0.20 g fish oil/kg BW/d; the treatment should be started 24 to 3 h before surgery, can be given as 3-6 hours infusion.~Intraoperative Day: No dose~Post OP (Day 0): 0.20 g fish oil/kg BW/d~Post OP ( Day 1 to max Day 7): 0.20 g fish oil/kg BW/d
Study NCT06279793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous 0.9% Sodium Chloride
Description: Intravenous 0.9% Sodium Chloride (volume 2 mL/kg BW/d)
Study NCT04145674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-methadone
Description: Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
Study NCT04145674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take one tablet of placebo once daily at 6 pm over a period of 30 days
Study NCT05136898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-102
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.
Study NCT05665400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bloomlife Lovelace FT
Description: Bloomlife Lovelace FT is a non-invasive, wireless, external measurement system used to measure accelerometer and electrophysiological signals on pregnant women with a singleton pregnancy, by acquiring biopotential signals from abdominal surface electrodes.
Study NCT05158244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Study Drug, once daily for 42 days
Study NCT05158244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 42 days
Study NCT06371404 — intervention group
Intervention type: DRUG
Intervention: Bavarostat
Description: Up to two injections of ≤ 5 mCi \[F18\] Bavarostat
Study NCT05431959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: immersion in Lake Hévíz, 36℃ sulphur, carbonate, calcium, magnesium, hydrogen carbonate and very light radon-content thermal-mineral water 15 times in 3 weeks 30-minute therapy sessions. The total mineral substance of the water is 754 mg/l.
Study NCT06450626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening Music Intervention
Description: Participants will listen to a music playlist while vitals are monitored, along with completing a pre- and post-assessment survey (both of which are the Edmonton Symptom Assessment Scale). Participants will also be asked a set of qualitative questions about their overall experience with the music therapy session.
Study NCT04970602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.
Study NCT06120621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 : VCST-phaco group , Arm 2 : phaco group.
Description: Arm 1 : VCST-phaco group , Arm 2 : phaco group.
Study NCT05016973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0mg/kg, Intravenous drip on days 1 every 21 days
Study NCT05016973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triplizumab
Description: 240mg, Intravenous drip on days 1 every 21 days
Study NCT04597996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education for students
Description: Web-based education will include modules on the following subjects;~* Mental health literacy knowledge level~* Improving help-seeking behavior~* Avoiding self-stigmatization in seeking psychological help
Study NCT05892302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Access to Asma Guardian website/app
Description: The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
Study NCT05892302 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed Access to Asma Guardian website/app
Description: Delayed access to the website/app. The Asma Guardian intervention application is a culturally-tailored web-platform that includes 3 tool kits. The contents of the tool kits include Asthma Specialty Care, Family Asthma Management, and Home Environmental Intervention.
Study NCT06539559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
Study NCT06539559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
Study NCT06539559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
Study NCT05316610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Confident Athletes
Description: The Body Confident Athletes program is a five-session in-person program designed to be delivered by coaches to their athletes. Groups should be of approximately 10 girls. The organizations will work with the community partner and researchers on how to schedule the intervention over a five-week period. These sessions can replace a regular sport practice each week or an additional session can be organized by the sport organizations. Each session will take approximately 60 minutes and will consist of four phases, including The Game Plan (5 mins), The Skills (20 mins), Game Time (20 mins), and The Final Score (15 mins). A variety of activity modalities are utilized to convey learning outcomes, including group and individual activities, and discussion-, writing- and movement-based activities.
Study NCT04187547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)
Study NCT04187547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.
Study NCT06247410 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rotigotine 8Mg/24Hrs Patch
Description: Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days
Study NCT04280640 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: A blood sample will be collected once, prior to treatment.
Study NCT05328219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gums with PEG solution
Description: Patients undergoing colonoscopy under experimental group was advised to take 2L of PEG solution and packets of sugarless sweet mint flavored chewing gums.~The patients are advised to Chew one stick of sugarless gum for at least 10 min after taking each glass of PEG solution and discard the chewing gum before taking next glass.
Study NCT05328219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT05166616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Correlative studies
Study NCT05166616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT05166616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide Analog
Description: Given PO
Study NCT04868500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMAZE™ Application
Description: Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
Study NCT04868500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMAZE™ Dashboard
Description: Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.
Study NCT05348447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoanalgesia
Description: intraoperative intercostal nerve freezing for post-operative pain control
Study NCT05348447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Pain Control
Description: Standard of Care Pain Control Post-operatively
Study NCT05609344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
Study NCT05609344 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SBIRT
Description: Low risk individuals will receive an educational pamphlet about alcohol use and the impact on health. Moderate Risk individuals will receive a brief alcohol intervention. High risk individuals will receive the brief alcohol intervention and be referred to specialty treatment.
Study NCT04846530 — intervention group
Intervention type: DEVICE
Intervention: RHA® 1, RHA® 2, RHA® 3, and RHA® 4
Description: For each subject, two spaced boluses (0.2 mL each) of the product will be implanted on the same side (left or right side) in the post auricular area of the subject per treatment assignment. The assignment will specify one of the RHA® products to the left ear and another product to the right ear. Each subject will have a total of four boluses.
Study NCT04927793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: \[14C\]EDP-938
Study NCT05786365 — intervention group
Intervention type: DRUG
Intervention: Ketalar 50 MG/ML Injectable Solution
Description: Ketamine will be administered to two different groups as 0.5 mg/kg and 1 mg/kg
Study NCT05479123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol three times a day
Description: Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided TID Week 2: 1 mg/kg/day divided TID Week 3: 2 mg/kg/day divided TID. Patients will stay on this dosage until their 3 month follow up visit.
Study NCT05479123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol twice a day
Description: Patients with larger (>2cm) or multiple (>1) hemangiomas in this arm will get propranolol in the following regimen:~Week 1: 0.5 mg/kg/day divided BID Week 2: 1 mg/kg/day divided BID Week 3: 2 mg/kg/day divided BID. Patients will stay on this dosage until their 3 month follow up visit.
Study NCT05479123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Patients with a small (\<2cm) isolated infantile hemangioma are prescribed timolol 0.5% ophthalmic drops, a topical beta-blocker(1 drop BID directly onto the hemangioma).
Study NCT05956808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Naida BTE hearing aid
Description: Newest generation of ultra-power Phonak BTE hearing aids
Study NCT05956808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Naida legacy BTE hearing aid
Description: Previous model/generation of the Naida BTE hearing aid
Study NCT04834830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pleural effusion will be examined for various cytokines and PD1-lymphocytes.
Description: Examination of pleural effusion
Study NCT05592496 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.
Description: After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.
Study NCT05592496 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral retromuscular rectus sheath block catheters usage for early postoperative analgesia after laparotomic gastrectomy.
Description: After surgery patients in the Block group receives continuous 0.125% (10-12 mg/h) bupivacaine infusion through rectus sheath catheters for 72 h in addition to fentanyl i/v infusion on postoperative day 0, and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery. Patients in the Control group receives NaCl 0,9% infusion and fentanyl i/v infusion on postoperative day 0 and ketorolac or trimeperidine injection on postoperative day 1-2 if necessery Pain intensity is going to be assessed in both groups using 0-100 mm Visual Analog Scale (VAS) at 24, 48 and 72 hour intervals after surgery at rest and during movement (by asking the patient to bend legs). Postoperative complications, hospital stay, comorbidities, the time taken to start walking after the surgery, bowel movements (time until first stool) were all examined.